Business
DiaMedica Provides a Business Update and Third Quarter 2020 Financial Results
Diabetic Kidney Disease Cohort Added to REDUX Study, Near Fully Enrolled FDA Grants Meeting Request for Review of Planned Stroke Study Program Completed $23M
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":"\n\nDiabetic Kidney Disease Cohort Added to REDUX Study, Near Fully Enrolled \n\n\nFDA Grants Meeting Request for Review of Planned Stroke Study Program \n\n\nCompleted $23M Public Offering of Common Shares\n\n\nConference Call with Management Tomorrow, November 5, at 7am CT\n\n\n MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business update and financial results for the three and nine months ended September 30, 2020. DiaMedica will host a conference call tomorrow, November 5, 2020, at 7:00 a.m. Central Time to discuss its business update and third quarter financial results.\n\nClinical Developments\n\nDM199 for the Treatment of Chronic Kidney Disease \n\nPhase II Clinical Study in CKD Caused by IgA Nephropathy and in African Americans with Hypertension – Enrollment Continues\n\nInitiation of Third Cohort in CKD Caused by Type II Diabetes Mellitus\n\nThe Phase II REDUX (latin for restore) trial is a multi-center, open-label investigation of approximately 90 evaluable participants with chronic kidney disease (CKD), who are being enrolled in three cohorts (30 per cohort). REDUX targets participants with CKD. Cohort I of the study is focused on non-diabetic, hypertensive African Americans with Stage II or III CKD and albuminuria, a group which is at greater risk for CKD than Caucasians. African Americans who have the APOL1 gene mutation are at an even higher risk for CKD. The study is designed to capture the APOL1 gene mutation as an exploratory biomarker in this cohort. Cohort II of the study is focused on participants with IgA Nephropathy (IgAN). Cohort III, is focused on participants with Type II diabetes mellitus, hypertension and albuminuria. Cohort III was added based upon additional data from DiaMedica’s recently completed ReMEDy Phase II acute ischemic stroke study which showed significantly improved estimated glomerular flow rates (eGFR), mean increase of 12.7mL/Min/1.732, and also reduced blood glucose levels compared to placebo in those subjects with elevated blood glucose levels at the time of enrollment.\n\nAs of October 30, 2020, DiaMedica had enrolled 49 subjects, including 11 African American subjects in Cohort I, 13 subjects with IgAN in Coh...